more

Aerpio Pharmaceuticals, Inc. (ARPO)

(Delayed Data from NSDQ)

$1.04 USD

+0.01 (0.96%)

Updated May 3, 2019 04:13 PM ET

After-Market: $1.05 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.03%
2	Buy	17.70%
3	Hold	9.37%
4	Sell	5.03%
5	Strong Sell	2.48%
S&P	500	11.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

Industry: NA

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

What Makes Aerpio Pharmaceuticals, Inc. (ARPO) a Strong Momentum Stock: Buy Now?

by Zacks Equity Research Published on December 14,2020

Does Aerpio Pharmaceuticals, Inc. (ARPO) have what it takes to be a top stock pick for momentum investors? Let's find out.

ARPOPositive Net Change

Hepion Pharmaceuticals (HEPA) Jumps: Stock Rises 9%

by Zacks Equity Research Published on December 11,2020

Hepion Pharmaceuticals (HEPA) saw a big move last session, as its shares jumped 9% on the day, amid huge volumes.

medical

Alkermes (ALKS) Outlines Value Enhancement Plan, Shares Up

by Zacks Equity Research Published on December 11,2020

Alkermes' (ALKS) Value Enhancement Plan is set to drive growth, improve operational and financial performance, as well as enhance shareholder value.

biotechs

Ultragenyx (RARE) Gets Orphan Drug Tag for Wilson Disease Drug

by Zacks Equity Research Published on December 10,2020

Ultragenyx (RARE) gets Orphan Drug Designation from the FDA for UX701 for the treatment of Wilson disease.

biotechs

Sesen Bio (SESN) Surges: Stock Moves 7.8% Higher

by Zacks Equity Research Published on December 09,2020

Sesen Bio (SESN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

medical

Checkmate (CMPI), Bristol Myers Ink Deal for Cancer Combo

by Zacks Equity Research Published on December 09,2020

Checkmate Pharmaceuticals (CMPI) inks deal with Bristol Myers to evaluate the combination of its CMP-001 and the latter's Opdivo.

biotechs

IDEAYA Biosciences (IDYA) Jumps: Stock Rises 8.2%

by Zacks Equity Research Published on December 08,2020

IDEAYA Biosciences (IDYA) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

medical

Chimerx's (CMRX) NDA for Brincidofovir Accepted by FDA

by Zacks Equity Research Published on December 08,2020

Chimerix's (CMRX) NDA for brincidofovir as a medical countermeasure for smallpox has been accepted by the FDA.

pharmaceuticals

FDA Approves Label Expannsion of Novo Nordisk's (NVO) Saxenda

by Zacks Equity Research Published on December 07,2020

Novo Nordisk (NVO) gets FDA approval for an updated label for Saxenda (liraglutide) injection 3 mg.

pharmaceuticals

Bayer (BAYRY) Inks Deal With Atara for CAR-T Cell Therapies

by Zacks Equity Research Published on December 07,2020

Bayer (BAYRY) inks a deal with Atara to sell the latter's to -generation, mesothelin-directed CAR-T cell therapies for the treatment of solid tumors.

pharmaceuticals

Alnylam (ALNY) Ends Enrollment in Advanced Hyperoxaluria Study

by Zacks Equity Research Published on December 04,2020

Alnylam (ALNY) completes enrollment in its phase III study of Oxlumo for the treatment of advanced primary hyperoxaluria type 1.

biotechs

Five Star (FVE) in Focus: Stock Moves 5.8% Higher

by Zacks Equity Research Published on December 04,2020

Five Star (FVE) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.

medical

Deere & Co, Chico's FAS, Aerpio Pharmaceuticals, TRACON Pharmaceuticals and Repligen Corp highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research Published on December 04,2020

Deere & Co, Chico's FAS, Aerpio Pharmaceuticals, TRACON Pharmaceuticals and Repligen Corp highlighted as Zacks Bull and Bear of the Day

BioNTech (BNTX) Surges: Stock Moves 6.2% Higher

by Zacks Equity Research Published on December 03,2020

BioNTech (BNTX) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

medical

3 Biotech Stocks to Buy on First Vaccine Approval Optimism

by Zacks Equity Research Published on December 03,2020

Here we discuss three potential stocks that can gain following mass availability of vaccine. Vaccination may release pent-up demand across sectors. It will also help biotechs progress with their clinical studies without any disruption.